Trails Edge Capital Partners, LP

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 2077247 ATLANTA, GA

Back to XENE Full portfolio

Position in XENE

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$25,586,000

-$1,175,663 QoQ

Shares Held

440,000

-26.3% QoQ

Ownership

0.455%

of shares outstanding

% of Portfolio

6.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2025

2 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in XENE Over Time

Shares Held

Position Value (USD)

Derivatives in XENE

reported options exposure · as of Mar 31, 2026

CallValue

CallShares

PutValue

$11,630,000

PutShares

200,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Trails Edge Capital Partners, LP holds $424,897,513 across 26 Biotechnology names. XENE ranks #6 (6.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	PCVX	Vaxcyte, Inc.	662,470	$38,496,131
2	DFTX	Definium Therapeutics, Inc.	1,738,110	$32,850,279
3	LBRX	Lb Pharmaceuticals Inc	1,319,362	$32,535,466
4	MIRM	Mirum Pharmaceuticals, Inc.	333,312	$30,791,362
5	NRIX	Nurix Therapeutics, Inc.	1,743,220	$27,019,910
6	XENE	Xenon Pharmaceuticals Inc. This page	440,000	$25,586,000
7	RVMD	Revolution Medicines, Inc.	245,000	$23,826,250
8	RCUS	Arcus Biosciences, Inc.	1,047,935	$22,635,396

All Filings in XENE

Export CSV

3 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$11,630,000	200,000	-54.5%	Put	Sole	2026-05-15
2026-03-31	$25,586,000	440,000	-26.3%	Shares	Sole	2026-05-15
2025-12-31	$26,761,663	597,092	—	Shares	Sole	2026-02-17
No filing history on record for this holder in this stock.